ArticleBMC cancer2025
Exploring research frontiers and emerging trends of tyrosine kinase inhibitors in the treatment of colorectal cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib.Journal of clinical medicine · 2026Review
- Bibliometric analysis and recent trends on tyrosine kinase inhibitors in leukemia.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTyrosine kinase inhibitors (TKIs) are a class of molecular targeted drugs designed to selectively inhibit tyrosine kinase activity associated with oncogenic signaling pathways and drivers, and have emerged as key therapeutic agents for colorectal cancer (CRC). The purpose of this study is to explore the research status and development trend of TKIs in CRC treatment.
methodsThe Web of Science Core Collection (WoSCC) database was systematically searched for publications related to TKIs for the treatment of CRC from 2015 to 2024. The CiteSpace visualization software were employed to visualization analysis.
resultsA total of 1151 papers published between 2015 and 2024 were included in this study. The USA was the most productive and influential country in this field. The University of Texas System and University of California System were identified as the most productive and most cited institutions, respectively. Cancers has the highest publication volume in this field. Trusolino Livio and Van Cutsem Eric were identified as the most prolific and most frequently co-cited authors, respectively. The article titled "Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways" published in Cancers in 2017, received the highest citation frequency. The emerging keywords that persisted into 2024 include "microsatellite instability", "biological evaluation", "drug discovery", "inhibitors", "regorafenib", "immunotherapy", and "T-cells".
conclusionCurrent research hotspots include development of novel TKIs, elucidation of TKIs resistance mechanisms and corresponding overcoming strategies, evaluation of TKIs efficacy and safety through biological assessments, and combination of TKIs with immunotherapy. Precision medicine, multimodal combination therapies, and interdisciplinary integration represent the frontier research areas and future development directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.